Drugs / PF-08046052
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05983133 | Nov 2023 → Apr 2026 | colorectal neoplasm, head and neck squamous cell carcinoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08046052 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05983133 ↗ |
| Route | Intravenous | “Given into the vein (IV; intravenously)” NCT05983133 ↗ |